Renata expands in Europe with Nordic launch of Parkadin
Renata PLC has launched Parkadin, the first and only registered generic version of Amantadine 100mg capsules in Finland, alongside simultaneous launches in Denmark, Sweden and Norway, marking a significant milestone in the company's international expansion strategy.
Manufactured at Renata's EU GMP-certified Rajendrapur General Facility, the dopaminergic medicine is indicated for the symptomatic treatment of Parkinson's disease, either as monotherapy or in combination with Levodopa.
Parkadin will be distributed via a strategic partnership using a common pack for the Nordic region, improving access to reimbursed medicines and reducing patients' out-of-pocket expenses.
Keep updated, follow The Business Standard's Google news channel
The launch strengthens Renata's expanding presence in Europe, building on its established position with Amantadine in the UK and EU markets, and further establishing the company as a global pharmaceutical manufacturer providing high-quality, affordable medicines.
